| Title |
Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer
|
|---|---|
| Published in |
Annals of Surgical Oncology, December 2017
|
| DOI | 10.1245/s10434-017-6307-3 |
| Pubmed ID | |
| Authors |
Tommaso Cornali, Paolo Sammartino, Nikolaos Kopanakis, Athina Christopoulou, Marialuisa Framarino dei Malatesta, Elias Efstathiou, Alessandra Spagnoli, Antonio Ciardi, Daniele Biacchi, John Spiliotis |
| Abstract |
More information is needed for selection of patients with peritoneal metastases from endometrial cancer (EC) to undergo cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC). This study analyzed clinical, pathologic, and treatment data for patients with peritoneal metastases from EC who underwent CRS plus HIPEC at two tertiary centers. The outcome measures were morbidity, overall survival (OS), and progression-free survival (PFS) during a median 5 year follow-up period. Uni- and multivariate analyses were performed to identify significant factors related to outcome. A total of 33 patients met the inclusion criteria and completed the follow-up period. At laparotomy, the median peritoneal cancer index (PCI) was 15 (range 3-35). The CRS procedure required a mean 8.3 surgical procedures per patient, and for 22 patients (66.6%), a complete cytoreduction was achieved. The mean hospital stay was 18 days, and major morbidity developed in 21% of the patients. The operative mortality was 3%. When surgery ended, HIPEC was administered with cisplatin 75 mg/m2 for 60 min at 43 °C. During a median follow-up period of 73 months, Kaplan-Meier analysis indicated a 5 year OS of 30% (median 33.1 months) and a PFS of 15.5% (median 18 months). Multivariate analysis identified the completeness of cytoreduction (CC) score as the only significant factor independently influencing OS. Logistic regression for the clinicopathologic variables associated with complete cytoreduction (CC0) for patients with metachronous peritoneal spread from EC who underwent secondary CRS plus HIPEC identified the PCI as the only outcome predictor. For selected patients with peritoneal metastases from EC, when CRS leaves no residual disease, CRS plus HIPEC achieves outcomes approaching those for other indications such as colon and ovarian carcinoma. |
X Demographics
The data shown below were collected from the profiles of 40 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 8 | 20% |
| Mexico | 4 | 10% |
| Spain | 4 | 10% |
| Brazil | 3 | 8% |
| Netherlands | 2 | 5% |
| Ecuador | 1 | 3% |
| Singapore | 1 | 3% |
| Norway | 1 | 3% |
| Australia | 1 | 3% |
| Other | 6 | 15% |
| Unknown | 9 | 23% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 27 | 68% |
| Scientists | 6 | 15% |
| Practitioners (doctors, other healthcare professionals) | 4 | 10% |
| Science communicators (journalists, bloggers, editors) | 3 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 34 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 18% |
| Researcher | 5 | 15% |
| Student > Master | 4 | 12% |
| Student > Bachelor | 4 | 12% |
| Student > Postgraduate | 2 | 6% |
| Other | 4 | 12% |
| Unknown | 9 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 59% |
| Social Sciences | 2 | 6% |
| Decision Sciences | 1 | 3% |
| Nursing and Health Professions | 1 | 3% |
| Engineering | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 9 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 October 2018.
All research outputs
#1,655,355
of 25,084,886 outputs
Outputs from Annals of Surgical Oncology
#277
of 7,161 outputs
Outputs of similar age
#37,405
of 454,285 outputs
Outputs of similar age from Annals of Surgical Oncology
#7
of 91 outputs
Altmetric has tracked 25,084,886 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,161 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 454,285 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 91 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.